Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337151 | 0.75 | HPGD (0.50) | KMT2AMEN1HTTL3MBTL1HPGD | |
| SCHEMBL9103138 | 0.73 | KMT2A (0.41) | KMT2AMEN1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL21838666 | 0.73 | — | — | |
| SCHEMBL15561658 | 0.73 | — | — | |
| SCHEMBL9101145 | 0.73 | KMT2A (0.52) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5065706 | 0.72 | KMT2A (0.47) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7201404 | 0.69 | SMN1; SMN2 (0.44) | KMT2AMEN1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL28656503 | 0.69 | CYP1A2 (0.47) | KMT2AMEN1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL2500069 | 0.69 | HPGD (0.48) | KMT2AMEN1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL28932692 | 0.69 | HPGD (0.48) | KMT2AMEN1ALDH1A1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |